Ischemic Neuroprotection by Insulin with Down-Regulation of Divalent Metal Transporter 1 (DMT1) Expression and Ferrous Iron-Dependent Cell Death

Background: The regulation of divalent metal transporter-1 (DMT1) by insulin has been previously described in Langerhans cells and significant neuroprotection was found by insulin and insulin-like growth factor 1 treatment during experimental cerebral ischemia in acute ischemic stroke patients and in a rat 6-OHDA model of Parkinson’s disease, where DMT1 involvement is described. According to the regulation of DMT1, previously described as a target gene of NF-kB in the early phase of post-ischemic neurodegeneration, both in vitro and in vivo, and because insulin controls the NFkB signaling with protection from ischemic cell death in rat cardiomyocytes, we evaluated the role of insulin in relation to DMT1 expression and function during ischemic neurodegeneration. Methods: Insulin neuroprotection is evaluated in differentiated human neuroblastoma cells, SK-N-SH, and in primary mouse cortical neurons exposed to oxygen glucose deprivation (OGD) for 8 h or 3 h, respectively, with or without 300 nM insulin. The insulin neuroprotection during OGD was evaluated in both cellular models in terms of cell death, and in SK-N-SH for DMT1 protein expression and acute ferrous iron treatment, performed in acidic conditions, known to promote the maximum DMT1 uptake as a proton co-transporter; and the transactivation of 1B/DMT1 mouse promoter, already known to be responsive to NF-kB, was analyzed in primary mouse cortical neurons. Results: Insulin neuroprotection during OGD was concomitant to the down-regulation of both DMT1 protein expression and 1B/DMT1 mouse promoter transactivation. We also showed the insulin-dependent protection from cell death after acute ferrous iron treatment. In conclusion, although preliminary, this evaluation highlights the peculiar role of DMT1 as a possible pharmacological target, involved in neuroprotection by insulin during in vitro neuronal ischemia and acute ferrous iron uptake.

[1]  J. Houeto,et al.  Trial of Lixisenatide in Early Parkinson's Disease. , 2024, The New England journal of medicine.

[2]  N. Jasnić,et al.  The Expression of Insulin in the Central Nervous System: What Have We Learned So Far? , 2023, International journal of molecular sciences.

[3]  A. Shpakov,et al.  Prospects for the Use of Intranasally Administered Insulin and Insulin-Like Growth Factor-1 in Cerebral Ischemia , 2023, Biochemistry (Moscow).

[4]  A. Shpakov,et al.  Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium , 2023, International journal of molecular sciences.

[5]  H. Ferris,et al.  The brain as an insulin-sensitive metabolic organ , 2021, Molecular metabolism.

[6]  A. Ahmadiani,et al.  Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6‐OHDA model of Parkinson's disease , 2021, CNS neuroscience & therapeutics.

[7]  Na Ding,et al.  Activation of NF-κB-Inducing Kinase in Islet β Cells Causes β Cell Failure and Diabetes. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Takhshid,et al.  The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major , 2020, Journal of Diabetes & Metabolic Disorders.

[9]  M. Memo,et al.  DMT1 Expression and Iron Levels at the Crossroads Between Aging and Neurodegeneration , 2019, Front. Neurosci..

[10]  P. Novak,et al.  Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study , 2019, PloS one.

[11]  M. Knutson.  Non-transferrin-bound iron transporters. , 2019, Free radical biology & medicine.

[12]  C. Nicholson,et al.  Interactions between insulin and diet on striatal dopamine uptake kinetics in rodent brain slices , 2018, The European journal of neuroscience.

[13]  M. Memo,et al.  Ferrous Iron Up-regulation in Fibroblasts of Patients with Beta Propeller Protein-Associated Neurodegeneration (BPAN) , 2017, Frontiers in genetics.

[14]  M. Chiong,et al.  Insulin/NFκB protects against ischemia-induced necrotic cardiomyocyte death. , 2015, Biochemical and biophysical research communications.

[15]  V. Lioutas,et al.  Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke , 2015, Translational Stroke Research.

[16]  Hongye Fan,et al.  FTO Inhibits Insulin Secretion and Promotes NF-κB Activation through Positively Regulating ROS Production in Pancreatic β cells , 2015, PloS one.

[17]  J. Seufert,et al.  The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems , 2014, Diabetes, obesity & metabolism.

[18]  Ann W. Kinyua,et al.  Leptin and insulin signaling in dopaminergic neurons: relationship between energy balance and reward system , 2014, Front. Psychol..

[19]  Jonghan Kim,et al.  Glucose metabolism in the Belgrade rat, a model of iron-loading anemia. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[20]  N. Andrews,et al.  Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic β cell fate in response to cytokines. , 2012, Cell metabolism.

[21]  M. A. De Luca,et al.  Late-onset Parkinsonism in NFκB/c-Rel-deficient mice , 2012, Brain : a journal of neurology.

[22]  P. Spano,et al.  1B/(−)IRE DMT1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NF-κB/RelA Acetylation at Lys310 , 2012, PloS one.

[23]  P. Spano,et al.  The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury , 2010, Cell Death and Disease.

[24]  C. Dinarello,et al.  Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines , 2010, Diabetologia.

[25]  P. Spano,et al.  Leptin Is Induced in the Ischemic Cerebral Cortex and Exerts Neuroprotection Through NF-&kgr;B/c-Rel–Dependent Transcription , 2009, Stroke.

[26]  Charles Duyckaerts,et al.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[27]  D. Inta,et al.  Bim and Noxa Are Candidates to Mediate the Deleterious Effect of the NF-κB Subunit RelA in Cerebral Ischemia , 2006, The Journal of Neuroscience.

[28]  Prasad N. Paradkar,et al.  Comparison of mammalian cell lines expressing distinct isoforms of divalent metal transporter 1 in a tetracycline-regulated fashion. , 2006, The Biochemical journal.

[29]  Prasad N. Paradkar,et al.  Nitric oxide transcriptionally down‐regulates specific isoforms of divalent metal transporter (DMT1) via NF‐κB , 2006, Journal of neurochemistry.

[30]  Dennis Higgins,et al.  DMT1: A mammalian transporter for multiple metals , 2003, Biometals.

[31]  P. Spano,et al.  Expression of functional NR1/NR2B‐type NMDA receptors in neuronally differentiated SK‐N‐SH human cell line , 2002, The European journal of neuroscience.

[32]  M. Hentze,et al.  Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: Implications for regulation and cellular function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Nancy Andrews,et al.  Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.

[34]  N. Andrews,et al.  Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene , 1997, Nature genetics.

[35]  Stephan Nussberger,et al.  Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.

[36]  Y. Agid,et al.  Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease , 1993, Journal of neurochemistry.

[37]  T. Ganz.  Iron and infection , 2017, International Journal of Hematology.